Physician profile
Gregory Wolf
NPI 1881653467
$884.78
in general payments reported to CMS, 2019-2025
14 companies · $51.15 in 2025
The $51.15 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.72 · 2020: $89.81 · 2021: $285 · 2022: $148 · 2023: $180 · 2024: $75.05 · 2025: $51.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $241.62 | 2020-2024 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $169.86 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.91 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $60.43 | 2019-2022 | |
| Allergan, INC. | $49.99 | 2020 | |
| Abbott Laboratories | $43.04 | 2023 | Freestyle Libre 3 |
| Pfizer INC. | $43.02 | 2023 | |
| Azurity Pharmaceuticals, INC. | $31.57 | 2025 | Edarbi |
| Endogastric Solutions, INC | $29.28 | 2019-2020 | |
| Acella Pharmaceuticals, LLC | $22.84 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.16 | 2023 | Quviviq |
| Novo Nordisk INC | $19.58 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $19.24 | 2021 | |
| Eisai INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.